We are interrupting our series on the value of your business for this important news regarding another major tax victory for business sellers.
Roughly 200 years ago, in an effort to promote commerce among the states and to stabilize their economies, the federal government established the United States Bank. One of the states thought to tax it . . . which, today, would seem absurd. The key legal concept on which the case turned was this: the power to tax is the power to destroy . . . and the power to regulate. Hold that thought.
For about 20 years, there has been a type of trust that 1) keeps assets in the individuals estate but 2) pays the income tax on its income as a separate taxpayer. Weve written about this type of trust a few times. The generic name is the incomplete-gift, non-grantor trust or ING trust.
The incomplete-gift means the trusts assets are still in your estate and, at death, you say who gets the money. And, because transfers to the trust are incomplete gifts, they are not subject to the gift tax. The non-grantor is tax-speak for the trust being a stand-alone taxpayer for income tax purposes. Importantly, the IRS has issued over 80 separate rulings confirming these tax characteristics. Click here to see one such ruling.
Top 10 Value Stocks To Own For 2018: TG Therapeutics, Inc.(TGTX)
- [By Brian Orelli]
TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.
Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.
- [By Lisa Levin] Gainers
Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
- [By Lisa Levin]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.
Top 10 Value Stocks To Own For 2018: National Health Investors, Inc.(NHI)
- [By Monica Gerson]
National Health Investors Inc (NYSE: NHI) is expected to post its quarterly earnings at $1.17 per share on revenue of $57.82 million.
Berkshire Hathaway Inc. (NYSE: BRK.B) is projected to post its quarterly earnings at $1.75 per share.
Top 10 Value Stocks To Own For 2018: Navistar International Corporation(NAV)
- [By Lee Jackson]
Navistar International Corp. (NYSE: NAV) was started with a Buy rating and a $36 price objective at Aegis Capital. That compares with a consensus target of $24.08. The 52-week range is $5.78 to $32.84. The stock closed yesterday at $30.93.
- [By Lee Jackson]
Icahn also was a buyer last week of Navistar International Corp. (NYSE: NAV). He acquireda total of 423.404 shares of the truck and engine maker at prices that ranged from $25.37 to $25.92. The total for the buy was listed at $11 million. The stock closed Friday at $27.49, so it looks like another well-timed buy. The 52-week range for the shares is $10.30 to $33.46, and the consensus price target is $26.79.
Top 10 Value Stocks To Own For 2018: Cotiviti Holdings, Inc. (COTV)
- [By Scott Rubin]
Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.
Top 10 Value Stocks To Own For 2018: Orexigen Therapeutics, Inc.(OREX)
- [By Keith Speights]
Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.
- [By Peter Graham]
A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:
- [By Cameron Saucier]
Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).
Top 10 Value Stocks To Own For 2018: Progressive Corporation (The)(PGR)
- [By Chris Lange]
Progressive Corp. (NYSE: PGR) is set to report its third-quarter results Tuesday morning as well. The analysts consensus estimates are $0.36 in EPS on revenue of $6.99 billion. Shares were changing hands at $48.67 on Fridays close. The consensus price target is $49.07, and the 52-week range is $30.99 to $49.75.
Top 10 Value Stocks To Own For 2018: Time Warner Inc.(TWX)
- [By Lee Jackson]
Time Warner Inc. (NYSE: TWX) was downgraded to Hold from Buy at Brean Capital. The 52-week range is $55.53 to $96.57. The consensus price target is $102.34. With the shares closing at $96.46, this could also be a valuation call.
- [By Matthew Briar]
The phrase “over the top television” or “OTT” for short, aren’t exactly new terms. The phrase/abbreviation was coined shortly after Netflix, Inc. (NASDAQ:NFLX) became a viable alternative to traditional cable television subscriptions a little less than a decade ago. The over-the-top battle didn’t get heated, though, until the past few months. But, now that some more gladiators are in the arena, sparks are starting to fly.
They’re still flying too, and should do so for a while if a small startup called Viva Entertainment Group Inc (OTCMKTS:OTTV) has anything to do with it it. See, while Netflix, Hulu — jointly owned by Time Warner, Walt Disney Co (NYSE:DIS) and Twenty-First Century Fox Inc (NASDAQ:FOXA) — and a whole slew of other new players in this market may want to take notice of this up-and-comer. At the same time, investors may want to take a step back and look at where the real money in the OTT business is going to be made over the course of the next several years. OTTV plays a prominent role in that picture.
Contrary to popular belief, Netflix isn’t the dominant name it used to be in the Internet-delivered television industry. Yes, it was the first on the scene as such was was able to carve out the biggest piece of the market. It’s largely become a commoditized business in the meantime though.
For example, outside of Hulu and Netflix, CBS Corporation (NYSE:CBS) has jumped into the fray with a service called CBS All Access. The product allows subscribers -for a nominal monthly fee – access a variety of CBS programming via the Internet. HBO, from Time Warner Inc (NYSE:TWX), has found some measurable success with its subscription-based Internet television service called HBO Go.
Sling TV, from DISH Network Corp (NASDAQ:DISH), is another one of the alternatives to the alternative that’s truly made a dent in the over the top market…. by aggregating a variety of television channels into an entire package and then selling that p
- [By Ashley Moore]
Here are all three of our top stocks to short…
Best Stocks to Short No. 3: Time Warner Inc. (NYSE: TWX)
For the first three quarters of 2016, Time Warner Inc. (NYSE: TWX) adjusted earnings slightly. The changes mostly reflected currency exchange rate fluctuations.
Top 10 Value Stocks To Own For 2018: Wynn Resorts, Limited(WYNN)
- [By Travis Hoium]
But Las Vegas Sands Corp. (NYSE:LVS) may not have had as strong a quarter as competitors like Melco Crown Entertainment Ltd (NASDAQ:MPEL) and Wynn Resorts, Limited (NASDAQ:WYNN). We’ll have to wait until the latter two report earnings to see how market share is trending, but Las Vegas Sands left a lot to be desired from a growth perspective.
- [By Lee Jackson]
Wynn Resorts Ltd. (NASDAQ: WYNN) hits our insider screens for the second week running. Daniel Wayson, a director at the gaming giant, bought a total of 37,500 shares of the stock at $93.83 per share. The total for the buy was set at $3,518,625. The consensus price target is $98.38. The stock changed handsat $88.34 on Friday’s close.
- [By Craig Jones]
Speaking on CNBC's "Fast Money Halftime Report", Pete Najarian said he noticed unusually high options volume in Melco Resorts & Entertainment Ltd(ADR) (NASDAQ: MLCO). He explained that traders were buying the November 24 calls Monday. Over 10,000 contracts were traded in the first half of the session and Najarian followed the trade. He already owns the stock and he believes it has some upside potential, because it's lagging behind Wynn Resorts, Limited (NASDAQ: WYNN).
Top 10 Value Stocks To Own For 2018: Opko Health Inc(OPK)
- [By Paul Ausick]
Opko Health Inc. (NASDAQ: OPK) dropped about 11.7% Wednesday to post a new 52-week low of $6.65 after closing at $7.53 on Tuesday. The stock’s 52-week high is $12.15. Volume of more than 15 million was nearly 4 times the daily average of around 4 million shares traded. On Tuesday the company reported a first-quarter loss.
- [By Cory Renauer]
Shares of multinational pharmaceutical and diagnostics companyOpko Health, Inc. (NASDAQ:OPK)are feeling the heat after reporting fourth-quarter and full-year 2016 earnings. Despite a major thumping late last year, the stock gave up another 10.5% as of 3:31 p.m. on Thursday.
- [By Demitrios Kalogeropoulos]
As for individual stocks, Cabela’s (NYSE:CAB) and Opko Health (NASDAQ:OPK) stood out by posting greater price declines than the broader market.
Opko Health fails a trial
Opko Health shares slumped 19% after the biotech announced disappointing results for one of its most advanced clinical trials. The human growth hormone injection, coded as hGH-CTP, failed to produce a statistically significant improvement over a placebo pill in its phase 3 study.
- [By Paul Ausick]
Opko Health Inc. (NASDAQ: OPK) dropped about 3.6% Monday to post a new 52-week low of $6.37 after closing at $6.61 on Friday. The stock’s 52-week high is $12.15. Volume was about 25% higher than the daily average of around 4.6 million shares. The company had no specific news.
- [By Paul Ausick]
Opko Health Inc. (NASDAQ: OPK) dropped nearly 15% on Thursday to record a new 52-week low of $7.13 against a high of $12.15. The stock closed at $8.37 on Wednesday. Volume was more than 3 times the daily average of around 4.9 million shares. The company reported a worse-than-expected loss after markets closed last night.
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on Kohlberg Kravis Roberts (KKR) , Opko Health (OPK) and Allergan (AGN) .
Cramer was bearish on Kimberly-Clark (KMB) , Novartis AG (NVS) , Chemours (CC) and Gulfport Energy (GPOR) .
Top 10 Value Stocks To Own For 2018: TRC Companies Inc.(TRR)
- [By Lisa Levin]
Shares of TRC Companies, Inc. (NYSE: TRR) got a boost, shooting up 16 percent to $7.53. TRC posted Q4 earnings of $0.20 per share on revenue of $132.3 million.